Valeant Pharmaceuticals (NYSE:VRX)(TSE:VRX) Monday agreed to buy dermatology products maker Medicis Pharmaceutical Corp. (NYSE:MRX) for about $2.6 billion in cash in a deal to strengthen its position in skin treatments and care.

Valeant, which merged with Canadian Biovail last June, said it has been in discussions with Cephalon for weeks, making "several private approaches" to the company, only to be disappointed each time and unable to strike a friendly deal.

NanoViricides (OTCBB:NNVC), a development stage company creating special purpose nanomaterials for antiviral therapy, said Wednesday its cash position at the end of the first quarter was "sufficient to carry out its initial clinical trials of its first drug candidate."

Pressure BioSciences, (OTCQB: PBIO), a company focused on developing its pressure cycling technology (PCT), says that researchers at Harvard Medical School have published a scientific paper describing a non-invasive method that could potentially screen for multiple diseases by gaining information about the gastrointestinal (GI) system using PCT and certain chemicals. 

The research firm said it expects the company to be profitable in 2014 as it increases its market share. The company "is poised for substantial growth with the aggressive commercialization and increased distributor agreements, of its Barocycler product portfolio, new offerings in its pipeline and promising new markets for its existing technology."

Shares of Pressure BioSciences (OTCQB:PBIO), a life sciences company focused on developing its pressure cycling technology (PCT), have been described as "deeply undervalued", according to Zacks Investment Research analyst Grant Zeng, when looking at the company's fundamentals.

Pressure BioSciences (OTCQB:PBIO), a life science company developing pressure cycling technology, or PCT, said that recent research has shown that PCT-based sample preparation methods have yielded improved quality and efficiency of test results.